Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

US regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

CEO resigns as Eli Lilly (LLY) dominates the weight loss drug market and compounders threaten the company's financial outlook ...

Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, ...

Novo Nordisk rode Ozempic's success to becoming Europe's top company. Now it's faltering and its CEO is out. Novo Nordisk rode Ozempic's success to becoming Europe's top company. Now it's faltering ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk board and Lars Fruergaard Jorgensen have jointly concluded that ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Eli Lilly has spent the last several years reintroducing itself to the public via a series of corporate campaigns. | Eli Lilly has spent the last several years reintroducing itself to the public via a ...